Evotec SE and Plectonic Biotech have launched a research collaboration to develop a novel immunotherapy for solid tumors by combining Evotec's BiTco platform with Plectonic's LOGIBODY® technology. This partnership aims to overcome challenges in T cell engager therapies by enhancing precision and potency through logic-gated tumor recognition and improved T cell activation. The collaboration will focus on generating preclinical proof-of-concept data to evaluate this new approach, potentially improving treatment outcomes for solid tumor patients. Both companies bring complementary technologies that could address tumor selectivity and safety issues in current therapies.
Argo Graphene Solutions Corp. has appointed Dr. Said Al-Hallaj, a renowned battery and energy storage scientist, to its Board of Directors. Dr. Al-Hallaj brings over 25 years of expertise in lithium-ion batteries, thermal management, and technology c...
The Amplify Digital Payments ETF (IPAY), focused on the digital payments sector, has significantly underperformed the S&P 500 over the past five years, posting losses in four of the last six years. Its top holdings include major payment processors li...
Solana (SOL) has surged 40% in the past month, trading around $101 with strong technical signals pointing to a potential rise to $150 by September's end. Analyst Ali Martinez highlights a bullish market structure, noting that SOL must surpass $110 an...
Avon Technologies secured a $20.3 million delivery order from the US Defense Logistics Agency for second-generation Advanced Combat Helmets through its Team Wendy Ceradyne business. This order completes the maximum volume authorized under the current...
Remixpoint sold its entire altcoin portfolio including Ethereum, Solana, XRP, and Dogecoin on September 1 for ¥878.8 million, realizing a profit of ¥117.8 million. The company now holds approximately 1,506 Bitcoin as its sole cryptocurrency, focusing...
